Meeting
2019 ASCO Annual Meeting
A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.
Authors
Emiliano Calvo
START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
Emiliano Calvo , Victor Moreno , Ruth Perets , Tamar Yablonski-Peretz , Nele Fourneau , Suzette Girgis , Yue Guo , Peter Hellemans , David Hokey , Natalia Pendas Franco , Qi Xia , Ravit Geva
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
NCT02829099
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2527)
DOI
10.1200/JCO.2019.37.15_suppl.2527
Abstract #
2527
Poster Bd #
171
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.
First Author: Sebastian Ochsenreither
Poster
2017 ASCO Annual Meeting
A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of BAL101553, a novel tumor checkpoint controller (TCC), administered as 48-hour infusion in adult patients with advanced solid tumors.
First Author: Markus Joerger
Poster
2016 ASCO Annual Meeting
A Phase 1 study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with advanced solid tumors.
First Author: Rebecca Sophie Kristeleit
Poster
2011 ASCO Annual Meeting
Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors.
First Author: P. A. Cohen